Abstract
Esophageal cancer (EC) is the eighth most common cancer in the world and the sixth leading cause of cancer-related mortality, with esophageal squamous-cell carcinoma (ESCC) accounting for over 80% of all cases. This study aimed to estimate the cost-effectiveness of nivolumab plus chemotherapy or nivolumab plus ipilimumab compared to chemotherapy alone as first line treatment for advanced or metastatic ESCC using U.S. payer perspective
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have